Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: CPG-oligonucleotide

Criteria

Inclusion Criteria:

• Glioblastoma

• Karnofsky Performance Status ≥ 60%

Exclusion Criteria:

• Severe or uncontrolled systemic disease

• Active auto-immune disease

• Uncontrolled epilepsia

• Platelets < 100 000/mm3 ; or Neutrophils <500 /mm3 ; or lymphocytes <300/ mm3